Beactica Therapeutics to present breakthrough in YAP-TEAD programme at the Hippo Pathway Drug Development Summit 2023

STOCKHOLM, May 16, 2023 /PRNewswire/ — Beactica Therapeutics AB, the Swedish precision oncology company, today announced that its YAP-TEAD programme has been selected for an oral presentation at the 2nd Hippo Pathway Targeted Drug Development Summit 2023. The conference will take place…

Leave a Reply

Your email address will not be published. Required fields are marked *